Injeção de indigotindissulfonato de sódio, USP como auxiliar na determinação da patência ureteral
Um estudo aberto, randomizado e multicêntrico para avaliar a segurança, eficácia e satisfação do médico de duas doses diferentes de Bludigo™ (injeção de indigotindisulfonato de sódio, USP) 0,8% quando usado como auxiliar na determinação da patência ureteral
This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Bludigo when used as an aid in the determination of ureteral patency.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure, age 18 to 85 years inclusive, will be screened for participation. Screening will occur within 30 days before study drug administration (Day of Surgery). After signing the informed consent, review of inclusion and exclusion criteria will be performed, the collection of concomitant medications, medical history, physical examination, baseline laboratory testing, 12-lead ECG, and vital sign measurements will be completed during the screening visit.
On the day of surgery (Day 1) subjects will be evaluated for eligibility for randomization. Eligible subjects will be stratified by BMI (<30.0 kg/m2or ≥ 30.0 kg/m2) and randomized in a 1:1 ratio to receive a dose of either Bludigo™ high dose (5.0 mL) or Bludigo™ low dose (2.5 mL). Each randomized subject will serve as his/her own control (i.e., intra-patient controlled) by receiving a dose of normal saline prior to receiving the randomized Bludigo™ dose.
All treated subjects will have a follow-up visit 7 to 30 days (± 2 days) after the procedure. A final telephone follow-up call will occur on Day 30 (± 2 days) in subjects who have the follow-up visit before Day 28. Safety assessments will include monitoring of AEs during and post the procedure, clinical laboratory tests, 12-Lead ECG, and vital sign measurements.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
New York
-
Albany, New York, Estados Unidos, 12008
- Albany Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subjects between ≥ 18 and ≤ 85 years old
- Subjects who signed a written IRB approved, informed consent form
- Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure
Exclusion Criteria:
- Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR <30 mL/min (calculated using the MDRD formula and standardized by using individual's body surface area) or need for dialysis in the near future, or having only 1 kidney
- Subjects with known severe hypersensitivity reactions to Bludigo™ or other dyes, including contrast dyes
- Known history of drug or alcohol abuse within 6 months prior to the time of screening visit
- Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g. major systemic diseases)
- Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures
- Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- Subjects with life expectancy < 6 months
- Requirement for concomitant treatment that could bias primary evaluation.
- Subjects who are pregnant or breast-feeding
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Saline
116 subjects treated with 5 ml of saline then crossover to treatment arm |
Placebo |
|
Experimental: High Dose
58 subjects randomly treated with 5 mL of drug |
Placebo Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Outros nomes:
|
|
Experimental: Low Dose
58 subjects randomly treated with 2.5 mL of drug |
Placebo Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Paired sample difference (Bludigo™-Saline) in urine jet conspicuity score .
Prazo: 10 minutes post study drug administration
|
Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:
Paired sample difference (Bludigo™-Saline) in conspicuity score (PSDCS). PSDCS will be calculated for each ureter (left or right) for each subject from each reviewer. |
10 minutes post study drug administration
|
|
Responders to Bludigo
Prazo: 10 Minutes post study drug administration
|
Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows:
A subject is considered a responder to Bludigo™ if there is >=1 point improvement in the conspicuity score following the Bludigo™- treatment vs the saline treatment and the conspicuity score for the Bludigo™ treatment must be (3, 4, or 5). The responder criteria will be assessed separately for each ureter (left or right) from each reviewer. |
10 Minutes post study drug administration
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of adverse events and serious adverse events.
Prazo: 30 days post study drug administration
|
Percentage of patients in each treatment group who experience an adverse event post treatment |
30 days post study drug administration
|
|
Changes in clinical safety laboratory values
Prazo: 30 days post study drug administration
|
Proportion of subjects with clinically important changes in clinical safety laboratory tests after treatment |
30 days post study drug administration
|
|
Changes in vital signs post treatment
Prazo: 30 days post study drug administration
|
Proportion of subjects with clinically important changes in vital signs after treatment |
30 days post study drug administration
|
|
Changes in ECG post treatment
Prazo: 30 days post study drug administration
|
Proportion of subjects with clinically important changes in ECGs after treatment |
30 days post study drug administration
|
|
Changes in blood pressure by dose group and BMI (kg/m^2)
Prazo: 30 days post study drug administration
|
Comparison of post treatment changes in blood pressure by dose group and BMI (kg/m^2) |
30 days post study drug administration
|
|
Changes in heart rate by dose group and BMI (kg/m^2)
Prazo: 30 days post study drug administration
|
Comparison of post treatment changes in heart rate by dose group and BMI (kg/m^2) |
30 days post study drug administration
|
|
Changes in pulse oximetry by dose group and BMI (kg/m^2)
Prazo: 30 days post study drug administration
|
Comparison of post treatment changes in pulse oximetry by dose group and BMI (kg/m^2) |
30 days post study drug administration
|
|
Physician Satisfaction
Prazo: 10 Minutes post study drug administration
|
To determine physicians' overall satisfaction with the Bludigo™ treatment by assessing the proportion of surgeons who agree using the 5-point Physician Satisfaction Agreement Scale (PSAS) with the statement: "Compared to the saline treatment, my ability to assess ureter patency was improved after the addition of Bludigo™."
|
10 Minutes post study drug administration
|
|
Time to visualization
Prazo: 10 minutes post study drug administration
|
To describe the time to visualization (TTV) of blue color in the ureteral jets flow following Bludigo™ treatment |
10 minutes post study drug administration
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Michelle Boytim, Ph.D., Provepharm SAS
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- PVP-22IC04
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .